 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Aastrom Biosciences, Inc.
|
-
First Patient Treated in Aastrom Adult Stem Cell Trial for Critical Limb Ischemia
(06/29/2007)
Five Sites Initiated for Phase IIb Trial in U.S.
Aastrom Biosciences, Inc. announced that the first critical limb ischemia (CLI) patient was treated at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, FL. The Company is evaluating its Vascular Repair Cell (VRC) product in a ...
-
FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
(05/09/2007)
Aastrom Biosciences, Inc. announced that the U.S. Food & Drug Administration (FDA) approved the Company's Investigational New Drug (IND) application to initiate a 120 patient Phase III clinical trial for the treatment of osteonecrosis (also known as ...
-
Aastrom Biosciences reports interim data from long bone non-union fracture clinical trial
(09/19/2006)
Aastrom Biosciences, Inc. reported additional interim results from patients enrolled in its U.S. Phase I/II multi-center clinical trial evaluating Tissue Repair Cells (TRCs) in the treatment of recalcitrant long bone non-union fractures. Of the 36 ...
-
Nelson M. Sims joins Aastrom Biosciences' Board of Directors
(02/15/2006)
Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Nelson M. Sims has been elected to the Company's Board of Directors. He will serve as a Class III Director whose initial term expires at the 2006 Annual Meeting of Shareholders. Mr. Sims ...
-
Stephen G. Sudovar elected to Aastrom Biosciences' board of directors
(08/04/2005)
Aastrom Biosciences, Inc. announced that Stephen G. Sudovar, former President and CEO of EluSys Therapeutics, Inc. and former President of Roche Laboratories, Inc., has been elected to the Company's Board of Directors effective July 29, 2005.Mr. ...
-
Aastrom Biosciences Receives Patent Expanding Coverage for its Single-pass Perfusion Technology
(01/17/2005)
Patent Extends Coverage from Stem Cell Population to Dendritic Cells
Aastrom Biosciences, Inc. announced that it has received a patent providing expanded coverage for the Company's single-pass perfusion technology to cover enhancing the biological functionality of human dendritic cells produced in cell culture. ...
-
Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain
(03/31/2004)
Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures
Ann Arbor, Michigan. Aastrom Biosciences, Inc. and its wholly owned subsidiary, Zellera AG, announced the initiation of a bone grafting clinical trial to be conducted by ITRT (Institut de Terapia Regenerativa Tisular) at Hospital General de ...
|
|
|
|
|
Top
